Nutriband (NTRB) Stock: Buy, Sell, or Hold?
NTRB - Nutriband Inc. Common Stock
$6.96
0.88 (14.47%)
▲
5d:
+23.62%
30d:
+126.34%
90d:
+97.73%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Sep 08, 2026
0d
Get Alerted When NTRB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: NTRB is 27.7% above its trading range ($5.45). Market expects 21.4% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: NTRB is 27.7% above its trading range ($5.45). Market expects 21.4% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$5.49
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$3.41
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 2.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: NTRB is currently trading at $6.96, which is considered extended relative to its 30-day fair value range of $3.11 to $5.45. From a valuation perspective, the stock is trading at a premium (Forward PE: 4.8) compared to its historical average (2.7). At these levels, the market is pricing in 21.4% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, NTRB is in a uptrend. The price is approaching resistance at $6.97. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 14.5% recently.
Market Sentiment: NTRB scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $15.00 (+115.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NTRB is in a uptrend. The price is approaching resistance at $6.97. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 14.5% recently.
Market Sentiment: NTRB scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $15.00 (+115.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$3.11 -
$5.45
Company Quality Score
31/100
(SELL)
Volume Confirmation
MODERATE
Confidence Score
18.1%
All Signals
- BEARISH: Price significantly overextended (+27.7% above its trading range)
- BEARISH: Weak technical setup (0/100)
- BULLISH: Strong upward momentum (+14.5%)
- BULLISH: Trading 115.5% below Wall St target ($15.00)
- NEUTRAL: Trading at premium valuation - market expects 21.4% growth which is achievable
- WARNING: Composite score 31/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.11 -
$5.45
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$4.22
Resistance Level
$6.97
Current Trend
Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
4.80
Wall Street Target
$15.00
(+115.5%)
Revenue Growth (YoY)
-29.7%
Valuation Premium vs History
+21.4% premium
PE vs Historical
4.8 vs 2.7
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+21.4%
(market-implied from PE analysis)
1-Year Target
$8.45
(+21%)
2-Year Target
$10.26
(+47%)
3-Year Target
$12.45
(+79%)
3-Yr Target (if PE normalizes)
(PE: 5→3)
PE COMPRESSION
$7.00
(+1%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: September 12, 2026 1:31 AM ET
Data refreshes hourly during market hours. Next update: 2:31 AM
Data refreshes hourly during market hours. Next update: 2:31 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NTRB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 52 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$88 | 50 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$55 | 49 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 50 HOLD |
